Newly-Woodlands, Texas-based MolecularHealth made headlines all throughout the month of October with news of the company ramping up its executive staff at their new U.S. headquarters, having brought on board a new Chief Medical Officer and a new CCO to the team, totaling six key members for their Woodlands office.
The company is now following up with new staffing news, having signed three members to its advisory board. Like MolecularHealth’s previous hirings, these new board members offer a high level of experience and expertise experience in pathology and oncology, and will bring their unique skill sets to bear in advising the company in preparation for its 2014 commercialization launch.
The first of the new appointees is Dr. Joyce O’Shaughnessy, M.D., who is a nationally recognized expert on breast cancer prevention and treatment. She is also Co-Chair of Breast Cancer Research at US Oncology, and also brings specific experience in serving in an advisory capacity, as she continues to serves as a member of US Oncology’s Scientific Advisory Board. Dr. O’Shaughnessy also brings an impressive education record, having received her medical degree from Yale Medical School, and is board certified in both internal medicine and medical oncology. Her education and background give her hands-on experience for further shaping the direction of MolecularHealth’s commercial presence in the U.S. and beyond.
Read more MolecularHealth articles here:
[feed url=”http://bionews-tx.com/news/news-tags/molecularhealth/feed” number=”5″ ]
Joining Dr. O’Shaughnessy on the advisory board is Burton M. Schwartz, M.D., F.A.C.P. Dr. Schwartz also boasts an impressive array of oncology-specific experience, as a founding member of Minnesota Oncology, the largest oncology practice in Minnesota. He too is a long-time board member of US Oncology, and received his medical degree from Meharry Medical College in Nashville, Tenn. and is triple board certified in internal medicine, medical oncology and hematology.
The third member of the new MolecularHealth advisory board is Thomas M. Wheeler, M.D., a Texas-based biotech and life sciences professional, who currently serves as Chairman of the Department of Pathology and Immunology at BCM, of which he is also an alumnus, having completed both medical school and residency there. Dr. Wheeler is also a board certified pathologist who specializes in prostate cancer.
Dr. Lloyd Everson, M.D., the CEO of MolecularHealth, whom BioNews Texas had the opportunity to interview recently, commented on these new appointments to the company’s advisory board, stating: “As we work toward bringing MolecularHealth’s platform to market in 2014, it’s crucial that we have a board of extremely high-level experts in oncology and pathology to complement our scientific and clinical development team. Drs. Wheeler, O’Shaughnessy and Schwartz all bring unique academic and research backgrounds, and see patients with a broad range of oncology challenges. I speak for the whole executive team when I say that we look forward to working with them as we shape our offering.”